AKRO - Wolfe starts Madrigal at outperform cites Rezdiffra launch
2024-06-11 13:28:02 ET
More on Madrigal Pharmaceuticals
- Madrigal May Not Be Able To Shrug GLP-1 Drugs For Long
- Madrigal Pharmaceuticals (MDGL) Q1 2024 Earnings Call Transcript
- Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label
- Madrigal sees ‘tremendous interest’ in new NASH drug Rezdiffra
- Madrigal Pharmaceuticals GAAP EPS of -$7.38 misses by $1.18